These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 30832855)

  • 1. Formulation and evaluation of cyclodextrin complexes for improved anticancer activity of repurposed drug: Niclosamide.
    Lodagekar A; Borkar RM; Thatikonda S; Chavan RB; Naidu VGM; Shastri NR; Srinivas R; Chella N
    Carbohydr Polym; 2019 May; 212():252-259. PubMed ID: 30832855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Direct cyclodextrin-based powder extrusion 3D printing for one-step production of the BCS class II model drug niclosamide.
    Pistone M; Racaniello GF; Arduino I; Laquintana V; Lopalco A; Cutrignelli A; Rizzi R; Franco M; Lopedota A; Denora N
    Drug Deliv Transl Res; 2022 Aug; 12(8):1895-1910. PubMed ID: 35138629
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preparation, characterization and in vivo evaluation of a formulation of dantrolene sodium with hydroxypropyl-β-cyclodextrin.
    Chen M; Wu Q; Jiang J; Jin X; Liu S; Wang M; Zhao C
    J Pharm Biomed Anal; 2017 Feb; 135():153-159. PubMed ID: 28027523
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cyclodextrin encapsulation enabling the anticancer repositioning of disulfiram: Preparation, analytical and in vitro biological characterization of the inclusion complexes.
    Benkő BM; Tóth G; Moldvai D; Kádár S; Szabó E; Szabó ZI; Kraszni M; Szente L; Fiser B; Sebestyén A; Zelkó R; Sebe I
    Int J Pharm; 2024 May; 657():124187. PubMed ID: 38697585
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Preparation of curcumin-hydroxypropyl-β-cyclodextrin inclusion complex by cosolvency-lyophilization procedure to enhance oral bioavailability of the drug.
    Li N; Wang N; Wu T; Qiu C; Wang X; Jiang S; Zhang Z; Liu T; Wei C; Wang T
    Drug Dev Ind Pharm; 2018 Dec; 44(12):1966-1974. PubMed ID: 30059244
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Niclosamide repositioning for treating cancer: Challenges and nano-based drug delivery opportunities.
    Barbosa EJ; Löbenberg R; de Araujo GLB; Bou-Chacra NA
    Eur J Pharm Biopharm; 2019 Aug; 141():58-69. PubMed ID: 31078739
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Octenylsuccinate hydroxypropyl phytoglycogen enhances the solubility and in-vitro antitumor efficacy of niclosamide.
    Xie Y; Yao Y
    Int J Pharm; 2018 Jan; 535(1-2):157-163. PubMed ID: 29113805
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of morin/hydroxypropyl-β-cyclodextrin inclusion complex: Enhancement of bioavailability, antihyperalgesic and anti-inflammatory effects.
    Lima BDS; Campos CA; da Silva Santos ACR; Santos VCN; Trindade GDGG; Shanmugam S; Pereira EWM; Marreto RN; Duarte MC; Almeida JRGDS; Quintans JSS; Quintans LJ; Araújo AAS
    Food Chem Toxicol; 2019 Apr; 126():15-24. PubMed ID: 30738132
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the aqueous solubilization of practically insoluble niclosamide by polyamidoamine (PAMAM) dendrimers and cyclodextrins.
    Devarakonda B; Hill RA; Liebenberg W; Brits M; de Villiers MM
    Int J Pharm; 2005 Nov; 304(1-2):193-209. PubMed ID: 16198076
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preparation, characterization, and cytotoxicity studies of niclosamide loaded mesoporous drug delivery systems.
    Pardhi V; Chavan RB; Thipparaboina R; Thatikonda S; Naidu V; Shastri NR
    Int J Pharm; 2017 Aug; 528(1-2):202-214. PubMed ID: 28596138
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inclusion complex of erlotinib with sulfobutyl ether-β-cyclodextrin: Preparation, characterization, in silico, in vitro and in vivo evaluation.
    Devasari N; Dora CP; Singh C; Paidi SR; Kumar V; Sobhia ME; Suresh S
    Carbohydr Polym; 2015 Dec; 134():547-56. PubMed ID: 26428157
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inclusion Complexation of Etodolac with Hydroxypropyl-beta-cyclodextrin and Auxiliary Agents: Formulation Characterization and Molecular Modeling Studies.
    Sherje AP; Kulkarni V; Murahari M; Nayak UY; Bhat P; Suvarna V; Dravyakar B
    Mol Pharm; 2017 Apr; 14(4):1231-1242. PubMed ID: 28248111
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lyophilization monophase solution technique for improvement of the physicochemical properties of an anticancer drug, flutamide.
    Elgindy N; Elkhodairy K; Molokhia A; Elzoghby A
    Eur J Pharm Biopharm; 2010 Feb; 74(2):397-405. PubMed ID: 19944160
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inclusion complexes of tadalafil with natural and chemically modified beta-cyclodextrins. I: preparation and in-vitro evaluation.
    Badr-Eldin SM; Elkheshen SA; Ghorab MM
    Eur J Pharm Biopharm; 2008 Nov; 70(3):819-27. PubMed ID: 18655829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Autophagy-Inducing Inhalable Co-crystal Formulation of Niclosamide-Nicotinamide for Lung Cancer Therapy.
    Ray E; Vaghasiya K; Sharma A; Shukla R; Khan R; Kumar A; Verma RK
    AAPS PharmSciTech; 2020 Sep; 21(7):260. PubMed ID: 32944787
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Nanosuspensions Containing Oridonin/HP-β-Cyclodextrin Inclusion Complexes for Oral Bioavailability Enhancement via Improved Dissolution and Permeability.
    Zhang X; Zhang T; Lan Y; Wu B; Shi Z
    AAPS PharmSciTech; 2016 Apr; 17(2):400-8. PubMed ID: 26187778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Host-guest inclusion system of norathyriol with β-cyclodextrin and its derivatives: preparation, characterization, and anticancer activity.
    Han B; Yang B; Yang X; Zhao Y; Liao X; Gao C; Wang F; Jiang R
    J Biosci Bioeng; 2014 Jun; 117(6):775-9. PubMed ID: 24508024
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of 4-sulphonato-calix[n]arenes and cyclodextrins on the solubilization of niclosamide, a poorly water soluble anthelmintic.
    Yang W; de Villiers MM
    AAPS J; 2005 Sep; 7(1):E241-8. PubMed ID: 16146345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Preparation and characterization of simvastatin/hydroxypropyl-beta-cyclodextrin inclusion complex using supercritical antisolvent (SAS) process.
    Jun SW; Kim MS; Kim JS; Park HJ; Lee S; Woo JS; Hwang SJ
    Eur J Pharm Biopharm; 2007 Jun; 66(3):413-21. PubMed ID: 17240129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Repositioning of Anti-parasitic Drugs in Cyclodextrin Inclusion Complexes for Treatment of Triple-Negative Breast Cancer.
    Priotti J; Baglioni MV; García A; Rico MJ; Leonardi D; Lamas MC; Menacho Márquez M
    AAPS PharmSciTech; 2018 Nov; 19(8):3734-3741. PubMed ID: 30255471
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.